BR9814087A - Processos para mediar a atividade do receptor de ppar-gama, e para tratar uma condição fisiológica em um paciente - Google Patents
Processos para mediar a atividade do receptor de ppar-gama, e para tratar uma condição fisiológica em um pacienteInfo
- Publication number
- BR9814087A BR9814087A BR9814087-6A BR9814087A BR9814087A BR 9814087 A BR9814087 A BR 9814087A BR 9814087 A BR9814087 A BR 9814087A BR 9814087 A BR9814087 A BR 9814087A
- Authority
- BR
- Brazil
- Prior art keywords
- ppar
- mediate
- treat
- patient
- processes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"PROCESSOS PARA MEDIAR A ATIVIDADE DO RECEPTOR DE PPAR-GAMA, E PARA TRATAR UMA CONDIçãO FISIOLóGICA EM UM PACIENTE" Um processo para mediar a atividade do receptor de PPAR-<sym> compreende o dito receptor de PPAR-<sym> com um composto da fórmula (I) em que: A é O, S, ou uma ligação química; B é O, S, SO, SO~ 2~, NR~ 1~, uma ligação química; D é O, S, NR~ 1~, (1),ou uma ligação química; E é uma ligação química; a é de 0 a 2; b é 0 ou 1; c é de 0 a 4; d é de 0 a 5; e é de 0 a 4; f é de 0 a 5; n é de 0 a 2; R é independentemente hidrogênio; R' é independentemente hidrogênio; R~ 1~ é independentemente hidrogênio; R~ 2~ é -(CH~ 2~)~ q~-X ou dois R~ 2~ vicinais quando juntos com os átomos de carbono através dos quais os dois R~ 2~ vicinais estão ligados formam cicloalquileno ou o R~ 1~ e o R~ 2~ geminais, quando juntos; q é de 0 a 3; X é hidrogênio.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6231897P | 1997-10-17 | 1997-10-17 | |
US6590297P | 1997-11-17 | 1997-11-17 | |
PCT/US1998/021947 WO1999020275A1 (en) | 1997-10-17 | 1998-10-16 | Therapeutic uses of quinoline derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9814087A true BR9814087A (pt) | 2000-10-03 |
Family
ID=26742119
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9814087-6A BR9814087A (pt) | 1997-10-17 | 1998-10-16 | Processos para mediar a atividade do receptor de ppar-gama, e para tratar uma condição fisiológica em um paciente |
Country Status (17)
Country | Link |
---|---|
US (1) | US6376512B1 (pt) |
EP (1) | EP1030665A4 (pt) |
JP (1) | JP2001520193A (pt) |
KR (1) | KR20010024533A (pt) |
CN (1) | CN1302206A (pt) |
AP (1) | AP2000001786A0 (pt) |
AU (1) | AU9696198A (pt) |
BG (1) | BG104432A (pt) |
BR (1) | BR9814087A (pt) |
CA (1) | CA2306825A1 (pt) |
EA (1) | EA200000427A1 (pt) |
HU (1) | HUP0101022A1 (pt) |
IL (1) | IL135673A0 (pt) |
NO (2) | NO20001962L (pt) |
OA (1) | OA11371A (pt) |
PL (1) | PL344977A1 (pt) |
WO (1) | WO1999020275A1 (pt) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1177187T3 (da) | 1999-04-28 | 2007-10-15 | Sanofi Aventis Deutschland | Diarylsyrederivater som PPAR-receptorligander |
DE60027420T2 (de) * | 1999-04-28 | 2006-11-16 | Aventis Pharma Deutschland Gmbh | Tri-aryl-säurederivate als ppar rezeptor liganden |
US7041691B1 (en) * | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
DE60005973T2 (de) * | 1999-08-27 | 2004-05-13 | Eli Lilly And Co., Indianapolis | Biaryl-oxa(thia)zolderivate und ihre verwendung als ppars modulatoren |
US6414002B1 (en) | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
TWI302149B (en) | 1999-09-22 | 2008-10-21 | Bristol Myers Squibb Co | Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method |
TWI262185B (en) * | 1999-10-01 | 2006-09-21 | Eisai Co Ltd | Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives |
US6586438B2 (en) * | 1999-11-03 | 2003-07-01 | Bristol-Myers Squibb Co. | Antidiabetic formulation and method |
JP2001261654A (ja) * | 2000-03-21 | 2001-09-26 | Mitsui Chemicals Inc | キノリン誘導体およびそれを有効成分として含有する核内レセプター作動薬 |
US6653332B2 (en) * | 2000-05-03 | 2003-11-25 | Tularik Inc. | Combination therapeutic compositions and method of use |
US20030171399A1 (en) * | 2000-06-28 | 2003-09-11 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
CA2433573A1 (en) | 2000-12-28 | 2002-07-11 | Takeda Chemical Industries, Ltd. | Alkanoic acid derivatives, process for their production and use thereof |
EP1911462A3 (en) | 2001-01-26 | 2011-11-30 | Schering Corporation | Compositions comprising a sterol absorption inhibitor |
TWI311133B (en) | 2001-04-20 | 2009-06-21 | Eisai R&D Man Co Ltd | Carboxylic acid derivativeand the salt thereof |
MXPA03011558A (es) | 2001-06-12 | 2004-03-26 | Wellstat Therapeutics Corp | Compuestos para el tratamiento de desordenes metabolicos. |
JPWO2003016265A1 (ja) * | 2001-08-17 | 2004-12-02 | エーザイ株式会社 | 環状化合物およびpparアゴニスト |
ATE386013T1 (de) | 2002-06-20 | 2008-03-15 | Astrazeneca Ab | Ortho-substituierte benzoesäurederivate zur behandlung von insulinresistenz |
SE0201937D0 (sv) * | 2002-06-20 | 2002-06-20 | Astrazeneca Ab | Therapeutic agents |
PL374860A1 (en) | 2002-07-09 | 2005-11-14 | Bristol-Myers Squibb Company | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method |
MXPA06003055A (es) * | 2003-09-17 | 2006-05-31 | Novartis Ag | Compuestos organicos. |
JP4981662B2 (ja) | 2004-05-05 | 2012-07-25 | ハイ・ポイント・ファーマスーティカルズ、エルエルシー | 新規の化合物、その製法と使用 |
WO2005105726A1 (en) | 2004-05-05 | 2005-11-10 | Novo Nordisk A/S | Novel compounds, their preparation and use |
CN100418532C (zh) * | 2005-06-17 | 2008-09-17 | 吕志民 | 治疗多种疾病的NF-κB化合物抑制剂 |
JP5052511B2 (ja) | 2005-06-30 | 2012-10-17 | ハイ ポイント ファーマシューティカルズ,エルエルシー | Pparデルタ活性化因子としてのフェノキシ酢酸 |
AU2006287521A1 (en) * | 2005-09-07 | 2007-03-15 | Plexxikon, Inc. | PPARactive compounds |
BRPI0620468A2 (pt) | 2005-12-22 | 2011-11-08 | Transtech Pharma Inc | ácidos fenóxi acéticos como ativadores de ppar delta |
JP2009529512A (ja) | 2006-03-09 | 2009-08-20 | ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー | 新規な化合物、それらの製造法、及び使用法 |
CA2663121C (en) | 2006-09-08 | 2016-01-19 | Rhode Island Hospital | Treatment, prevention, and reversal of alcohol-induced brain disease |
US7645616B2 (en) | 2006-10-20 | 2010-01-12 | The University Of Hong Kong | Use of lipocalin-2 as a diagnostic marker and therapeutic target |
NZ588374A (en) | 2008-04-30 | 2012-11-30 | Wellstat Therapeutics Corp | Tetrazole compounds for reducing uric acid |
BRPI1011318A2 (pt) | 2009-06-09 | 2019-09-24 | California Capital Equity Llc | derivados de triazina e suas aplicações terapêuticas |
EP2440048B8 (en) | 2009-06-09 | 2015-12-16 | NantBioScience, Inc. | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling |
BRPI1011319A2 (pt) | 2009-06-09 | 2016-06-21 | California Capital Equity Llc | derivados de triazina benzil-substituídos e suas aplicações terapêuticas |
CA2804593C (en) | 2010-07-09 | 2015-11-24 | Pfizer Limited | Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors |
CA2804351A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
ES2532357T3 (es) | 2010-07-12 | 2015-03-26 | Pfizer Limited | Derivados de sulfonamida como inhibidores de Nav1.7 para el tratamiento del dolor |
US9096500B2 (en) | 2010-07-12 | 2015-08-04 | Pfizer Limited | Acyl sulfonamide compounds |
WO2012007861A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors |
WO2012007869A2 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
US10099993B2 (en) * | 2014-04-06 | 2018-10-16 | Sanford-Burnham Medical Research Institute | Metabotropic glutamate receptor positive allosteric modulators (PAMS) and uses thereof |
CA3187998A1 (en) * | 2020-08-04 | 2022-02-10 | Angela ZAMPELLA | Quinoline compounds as selective and/or dual modulators of bile acid receptors and leukotriene cysteinyl receptors |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3174901A (en) * | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
US4920132A (en) * | 1987-11-03 | 1990-04-24 | Rorer Pharmaceutical Corp. | Quinoline derivatives and use thereof as antagonists of leukotriene D4 |
US4920130A (en) * | 1987-11-02 | 1990-04-24 | Rorer Pharamceutical Corp. | Quinoline derivatives and use thereof as antagonists of leukotriene D4 |
NZ276577A (en) * | 1993-11-29 | 1997-11-24 | Merrell Pharma Inc | 2-acyl-4-benzenesulphonyliminoquinoline and -chromene derivatives |
DE69512495T2 (de) * | 1994-10-27 | 2000-02-03 | Yoshitomi Pharmaceutical | Verfahren zur Herstellung von Chinolin-2-yl-benzoesäure |
DE69728375T2 (de) * | 1996-01-02 | 2005-02-10 | Aventis Pharmaceuticals Inc. | Substituierte (aryl, heteroaryl, arylmethyl oder heteroarylmethyl) hydroxamisaeureverbindungen |
-
1998
- 1998-10-16 JP JP2000516672A patent/JP2001520193A/ja active Pending
- 1998-10-16 AU AU96961/98A patent/AU9696198A/en not_active Abandoned
- 1998-10-16 BR BR9814087-6A patent/BR9814087A/pt not_active Application Discontinuation
- 1998-10-16 CN CN98811303A patent/CN1302206A/zh active Pending
- 1998-10-16 KR KR1020007004131A patent/KR20010024533A/ko not_active Application Discontinuation
- 1998-10-16 EP EP98951075A patent/EP1030665A4/en not_active Withdrawn
- 1998-10-16 PL PL98344977A patent/PL344977A1/xx unknown
- 1998-10-16 IL IL13567398A patent/IL135673A0/xx unknown
- 1998-10-16 EA EA200000427A patent/EA200000427A1/ru unknown
- 1998-10-16 WO PCT/US1998/021947 patent/WO1999020275A1/en not_active Application Discontinuation
- 1998-10-16 CA CA002306825A patent/CA2306825A1/en not_active Abandoned
- 1998-10-16 HU HU0101022A patent/HUP0101022A1/hu unknown
-
2000
- 2000-01-27 US US09/490,897 patent/US6376512B1/en not_active Expired - Fee Related
- 2000-04-07 AP APAP/P/2000/001786A patent/AP2000001786A0/en unknown
- 2000-04-13 OA OA1200000106A patent/OA11371A/en unknown
- 2000-04-14 NO NO20001962A patent/NO20001962L/no not_active Application Discontinuation
- 2000-05-15 BG BG104432A patent/BG104432A/bg unknown
- 2000-06-16 NO NO20003107A patent/NO20003107L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO20003107D0 (no) | 2000-06-16 |
PL344977A1 (en) | 2001-11-19 |
CA2306825A1 (en) | 1999-04-29 |
AU9696198A (en) | 1999-05-10 |
KR20010024533A (ko) | 2001-03-26 |
EP1030665A4 (en) | 2002-11-27 |
NO20003107L (no) | 2000-07-26 |
EP1030665A1 (en) | 2000-08-30 |
IL135673A0 (en) | 2001-05-20 |
WO1999020275A1 (en) | 1999-04-29 |
BG104432A (bg) | 2000-12-29 |
NO20001962L (no) | 2000-06-16 |
EA200000427A1 (ru) | 2001-02-26 |
HUP0101022A1 (hu) | 2001-10-28 |
OA11371A (en) | 2004-01-28 |
US6376512B1 (en) | 2002-04-23 |
NO20001962D0 (no) | 2000-04-14 |
JP2001520193A (ja) | 2001-10-30 |
CN1302206A (zh) | 2001-07-04 |
AP2000001786A0 (en) | 2000-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9814087A (pt) | Processos para mediar a atividade do receptor de ppar-gama, e para tratar uma condição fisiológica em um paciente | |
BR0015307A (pt) | Composto, composição, composição farmacêutica, métodos para tratar um distúrbio que é criado pela ou é dependente da disponibilidade diminuìda de serotonina, norepinefrina ou dopamina, e para inibir a absorção de norepinefrina sináptica, de serotonina sináptica e de dopamina sináptica em um paciente em necessidade destas, e, conjunto | |
BR9713914A (pt) | Composto, uso do mesmo, composição farmacêutica, e processo para tratar um paciente sofrendo de um distúrbio que é susceptìvel a tratamento com um agonista da trombopoietina. | |
BRPI0411255A (pt) | composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto | |
MY132626A (en) | CARBAZOLYL-SUBSTITUTED ETHANOLAMINES AS SELECTIVE ß-3 AGONISTS | |
BR9813524A (pt) | Processos para tratamento de toxicidades associadas com a administração de um agente terapêutico a um mamìfero, para tratamento de toxicidades associadas com a exposição de um mamìfero à terapia de radiação, para tratamento de neuro- ou nefrodistúrbios em um humano, e, para tratamento de distúrbios e sintomas clìnicos associados com diabetes do tipo i ou do tipo ii em um humano | |
BR9911779A (pt) | Benzotiofenos, benzofuranos e indóis úteis no tratamento de resistência à insulina e hiperglicemia | |
MX9802130A (es) | Agonistas adrenergicos beta3 selectivos. | |
BR0315981A (pt) | Composições para tratamento de tecidos que contêm diferentes silicones, processo para a sua preparação e método para a sua utilização | |
BR9808953A (pt) | Composto, processo para tratar um distúrbio mediado pela ciclooxigenase-2 em um paciente, e, composição farmacêutica | |
BR9709427A (pt) | Oxa ácidos e compostos relacionados para tratamento de condições da pele | |
BR9612423A (pt) | Composto, composição farmacêutica, e, processo para tratar um estado doentio. | |
BR0211400A (pt) | Tratamento de distrofia muscular com células de sangue do cordão | |
BR9713921A (pt) | Composto, composição farmacêutica, processo para tógico capaz de ser modulado através da inibição do fator xa | |
BR9805297A (pt) | Derivados de 1,3,8-triazaspiro (4,5) decan-4on. | |
BR9610481A (pt) | Agonistas adrenérgicos beta seletivos | |
DE69506686T2 (de) | Verwendung von bis (amidinobenzidazolen) zur herstellung eines medikamentes für die hemmung der retroviral integrase | |
BR0011578A (pt) | Utilização do s-enantiÈmero de citalopram para tratamento de distúrbio de ansiedade geral ou ataques de pânico | |
BR9808042A (pt) | Composto, composição farmacêutica, e, processo para preparação de compostos. | |
ATE199829T1 (de) | Meta substituierte arylalkylamine und therapeutische und diagnostische verwendung davon | |
PT93588A (pt) | Processo para a preparacao de analogos da adenosina | |
BR9712503A (pt) | Derivados anticonvulsivos úteis no tratamento de dor neuropática | |
BR9812780A (pt) | 2-aril-3-aroilbenzo[b]tiofenos úteis para o tratamento de sìndrome da perda de estrogênio | |
ATE310517T1 (de) | Cabergolin und pramipexol zur behandlung von krankheiten des zentralnervensystems, insbesondere parkinsonscher krankheit | |
MD970254A (en) | Use of melatonine for treatment of patients having a medicamental dependence |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA10 | Dismissal: dismissal - article 33 of industrial property law | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |